Tazemetostat in patients with recurrent/refractory and/or metastatic MPNST
This phase 2, open label, single arm study will investigate the use of tazemetostat in patients with recurrent/refractory and/or metastatic malignant peripheral nerve sheath tumors.
- Investigator
- Joanne Lagmay
- Status
- Accepting Candidates
- Ages
- 12 Years - 99 Years
- Sexes
- All
Neuroblastoma Maintenance Therapy Trial (NMTT)
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ±…
- Investigator
- Joanne Lagmay
- Status
- Accepting Candidates
- Ages
- 1 Year - 30 Years
- Sexes
- All